Drug Trial Radar · NCT07256301
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 3, 2024
Primary completion
Aug 31, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions
- PNH - Paroxysmal Nocturnal Hemoglobinuria
Interventions
EA5Biological
All treatments were given as IV infusions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.